Earlier Steroid Use Does Not Decrease the Severity or Duration of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Large B-Cell Lymphoma (LBCL) Who Received Axicabtagene Ciloleucel (axi-cel).

Axi-cel continues to show durable responses in a subset of patients with LBCL (Neelapu et al. 2023). Management of two common axi-cel toxicities, CRS and ICANS, includes the use of steroids (Santomasso et al. 2021), although the optimal dose and timing remains unknown. In this single-center retrospective study we investigated the importance of steroid treatment timing by comparing patients treated before and after the implementation of an early steroid treatment standard operating procedure (SOP) for low grade CRS and ICANS at the University of Rochester.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 247 Source Type: research